{
    "clinical_study": {
        "@rank": "158234", 
        "arm_group": [
            {
                "arm_group_label": "Sertraline", 
                "arm_group_type": "Active Comparator"
            }, 
            {
                "arm_group_label": "Cognitive Behavioural Therapy", 
                "arm_group_type": "Active Comparator"
            }, 
            {
                "arm_group_label": "Combined Therapy", 
                "arm_group_type": "Active Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "Th purpose of this study is to determine whether dual psychological and pharmacological\n      treatment is superior to either mono-therapy alone in the treatment of postnatal depression."
        }, 
        "brief_title": "A Randomised Trial of Sertraline, Cognitive Behaviour Therapy & Combined Therapy for Postnatal Depression", 
        "completion_date": {
            "#text": "April 2005", 
            "@type": "Actual"
        }, 
        "condition": [
            "Depression", 
            "Anxiety"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Anxiety Disorders", 
                "Depression", 
                "Depressive Disorder", 
                "Depression, Postpartum"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Women with an infant > 2 months and < 8 months of age\n\n          -  Infant born after a full-term pregnancy\n\n          -  Infant born with no congenital abnormalities\n\n          -  Diagnosis of depression with postnatal onset according to the Diagnostic and\n             Statistical Manual of Mental Disorders 4th Edition (DSM-IV).\n\n        Exclusion Criteria:\n\n          -  positive serum pregnancy test;\n\n          -  concurrent psychiatric disorder (excepting co-morbid anxiety);\n\n          -  recent history of antidepressant usage (within the last month);\n\n          -  history of major allergy or drug allergy;\n\n          -  history of substance abuse;\n\n          -  prior non-response to sertraline, or prior non-response to adequate trials of two\n             selective serotonin reuptake inhibitors (SSRIs);\n\n          -  predisposition to headache, migraine or nausea;\n\n          -  tobacco habit in excess of 10 cigarettes per day;\n\n          -  caffeine consumption in excess of 6 cups of coffee/tea or cola-flavoured drinks per\n             day;\n\n          -  ongoing dental work;\n\n          -  extreme levels of depression (psychotic);\n\n          -  suicidal intent;\n\n          -  participation in any medical trial within the previous three months;"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "40 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "45", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "April 22, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02122393", 
            "org_study_id": "H2001/01263"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Sertraline", 
                    "Combined Therapy"
                ], 
                "intervention_name": "Sertraline", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Cognitive Behavioural Therapy", 
                    "Combined Therapy"
                ], 
                "intervention_name": "Cognitive Behavioural Therapy", 
                "intervention_type": "Behavioral"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Sertraline"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "April 27, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Melbourne", 
                    "country": "Australia", 
                    "state": "Victoria", 
                    "zip": "3081"
                }, 
                "name": "Austin Health"
            }
        }, 
        "location_countries": {
            "country": "Australia"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Randomised, Controlled Evaluation of Sertraline, Cognitive Behaviour Therapy & Combined Therapy for Postnatal Depression", 
        "overall_official": [
            {
                "affiliation": "University of Melbourne", 
                "last_name": "Jeannette Milgrom, PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Austin Health", 
                "last_name": "Alan W Gemmill, PhD", 
                "role": "Study Director"
            }
        ], 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Australia: Austin Health HREC", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "April 2005", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Beck Depression Inventory", 
            "safety_issue": "No", 
            "time_frame": "24 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02122393"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Melbourne", 
            "investigator_full_name": "Jeannette Milgrom", 
            "investigator_title": "Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Beck Anxiety Inventory", 
                "safety_issue": "No", 
                "time_frame": "24 weeks"
            }, 
            {
                "measure": "Parenting Stress Index", 
                "safety_issue": "No", 
                "time_frame": "24 weeks"
            }
        ], 
        "source": "University of Melbourne", 
        "sponsors": {
            "collaborator": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "University of Melbourne", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2002", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}